Mannitol (Mannitol)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceMannitolMannitol
Similar drugsTo uncover
  • Bronchitol-Pharmaxis
    powder d / inhal. 
    Pharmaxis Co., Ltd.     Australia
  • Mannitol
    solution d / infusion 
    BIOCHEMIST, OJSC     Russia
  • Mannitol
    solution d / infusion 
    KRASFARMA, JSC     Russia
  • Mannitol
    solution in / in 
    ESKOM NPK, OAO     Russia
  • Mannitol
    solution d / infusion 
    Kursk Biofactory - BIOK, FKP     Russia
  • Mannitol
    solution d / infusion 
    GROTEKS, LLC     Russia
  • Mannitol
    solution d / infusion 
    EAST-FARM, CJSC     Russia
  • Mannitol
    solution d / infusion 
    FIRM MEDPOLIMER, JSC     Russia
  • Mannitol
    solution d / infusion 
    BIOSINTEZ, PAO     Russia
  • Mannitol-Kelun-Kazpharm
    solution d / infusion 
    Kelun-Kazfarm, TOO     The Republic of Kazakhstan
  • Mannitol-SF
    solution d / infusion 
    Sphera-Pharm, OOO     Russia
    • Dosage form: & nbspsolution for infusions
    Composition:Active substance:
    Mannitol -150.0 mg

    Excipients:
    Sodium chloride 9.0 mg
    Water for injection - up to 1 ml

    Theoretical osmolarity: 1132 mOsm / l.

    Description:

    A clear, colorless solution.

    Pharmacotherapeutic group:diuretic agent.
    ATX: & nbsp

    R.05.C.B.16   Mannitol

    B.05.C.X.04   Mannitol

    B.05.B.C.01   Mannitol

    A.06.A.D.16   Mannitol

    Pharmacodynamics:

    Osmotic diuretic. By increasing the osmotic pressure of blood plasma and filtration in the renal glomeruli without subsequent tubular reabsorption leads to retention of water in the renal tubules and an increase in the volume of urine.Effective mannitol, mainly in the proximal tubules, although the effect is preserved to a small extent in the descending loop of the nephron and in the collecting tubes. Does not penetrate through cellular and tissue barriers (for example, blood-brain barrier), does not increase the content of residual nitrogen in the blood. Raising the osmolarity of the blood plasma, causes the fluid to move from the tissues (in particular, the eyeball, brain) to the vascular bed. Does not affect glomerular filtration. Diuresis is accompanied by a moderate increase in natriuresis without a significant effect on the excretion of potassium ions (K +). The diuretic effect is higher, the higher the concentration (dose). Ineffective in violation of the filtration function of the kidneys, as well as in the case of azotemia in patients with cirrhosis and ascites. Causes an increase in the volume of circulating blood (BCC).

    Pharmacokinetics:

    The volume of mannitol distribution corresponds to the volume of the extracellular fluid, since it is distributed only in the extracellular sector. Mannitol can undergo a slight metabolism in the liver with the formation of glycogen. The half-life is about 100 minutes. The drug is excreted by the kidneys.The excretion of mannitol is regulated by glomerular filtration, without significant tubular reabsorption and secretion. After intravenous administration of 100 g mannitol, 80% of it is determined in urine for 3 hours. In patients with renal failure, the half-life of mannitol may increase to 36 hours.

    Indications:Edema of the brain, intracranial hypertension (with renal and / or liver failure); oliguria in acute renal and / or hepatic insufficiency with preserved filtration ability of kidneys (as part of combination therapy), posttransfusion complications after introduction of incompatible blood, forced diuresis in case of poisoning with barbiturates, salicylates; prevention of hemolysis in surgical interventions with the use of extracorporeal circulation in order to prevent kidney ischemia and associated acute renal failure.
    Contraindications:Hypersensitivity to the components of the drug, anuria on the background of acute necrosis of the renal tubules, left ventricular heart failure (especially accompanied by pulmonary edema), chronic heart failure, hemorrhagic stroke,subarachnoid hemorrhage (except for bleeding during trepanation of the skull), dehydration of severe severity, hyponatremia, hypochloraemia, hypokalemia.
    Children under 18 years of age due to insufficient data on the application.

    Carefully:

    Pregnancy, lactation, elderly.

    Pregnancy and lactation:

    Mannitol is used only in cases where the expected benefit to the mother exceeds the possible risk to the fetus or child.

    Dosing and Administration:Intravenously (slowly drip or drip).
    The preventive dose is 0.5 g / kg, the therapeutic dose is 1-1.5 g / kg; the daily dose should not exceed 140-180 g. Before administration, the preparation should be heated to a temperature of 37 ° C (it is possible on a water bath). In operations with artificial circulation, 20-40 g of mannitol are injected into the apparatus immediately before the start of perfusion.
    Patients with oliguria should first be given an intravenous drip test dose (200 mg / kg) for 3-5 minutes. In the absence of an increase in the rate of diuresis to 30-50 ml / h for 2-3 hours, further administration of the drug should be discarded.

    Form release / dosage:Solution for infusions 150 mg / ml.
    Packaging:For 250, 500 ml in polyethylene bottles without a cap or with a welded euro bag or plastic cap or infusion plug. For 1 bottle in a hermetically sealed packet of polymer film or without a package in a pack of cardboard box together with instructions for use.
    From 1 to 96 bottles without packs in hermetically sealed bags or without packages with an equal number of instructions for use in a corrugated box (for hospitals).
    Terms of leave from pharmacies:On prescription
    Registration number:LP-001947
    Date of registration:24.12.2012
    The owner of the registration certificate:EAST-FARM, CJSC EAST-FARM, CJSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp03/21/2014
    Illustrated instructions
      Instructions
      Up